PTC Therapeutics | PTCT - Interest Expense On Debt

Stock Price
74.71
Daily Change
-0.17 -0.23%
Monthly
-2.67%
Yearly
51.30%
Q1 Forecast
73.20

PTC Therapeutics reported $2.64B in Interest Expense on Debt for its fiscal quarter ending in September of 2025.





Interest Expense On Debt Change Date
Acadia Pharmaceuticals USD 0 4.12M Sep/2024
Alnylam Pharmaceuticals USD 44.4M 4.15M Sep/2025
Amgen USD 685M 9M Sep/2025
Biogen USD 72.6M 12.6M Jun/2025
BioMarin Pharmaceutical USD 2.58M 100K Sep/2025
Cytokinetics USD 26.32M 2.06M Sep/2025
Daiichi Sankyo JPY 2.16B 1.33B Dec/2025
Gilead Sciences USD 254M 6M Jun/2025
Incyte USD 592K 2K Sep/2025
Ionis Pharmaceuticals USD 18M 1000K Sep/2025
Ironwood Pharmaceuticals USD 8.74M 506K Dec/2024
Novartis USD 281M 8M Sep/2025
Pfizer USD 652M 2M Sep/2025
PTC Therapeutics USD 2.64B 2.61B Sep/2025
Roche Holding CHF 304M 7.5M Jun/2025
Sarepta Therapeutics USD 7.56M 2.33M Sep/2025
TG Therapeutics USD 6.72M 4K Sep/2025
Ultragenyx Pharmaceutical USD 14.15M 108K Sep/2025
Vertex Pharmaceuticals USD 3.3M 400K Sep/2025
Xencor USD 7.66M 578K Sep/2025